Peter Lawson
Stock Analyst at Barclays
(1.19)
# 3,553
Out of 4,944 analysts
97
Total ratings
34.52%
Success rate
-15.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Equal-Weight | $17 → $3 | $5.09 | -41.06% | 4 | Jul 23, 2025 | |
| EXEL Exelixis | Maintains: Equal-Weight | $29 → $40 | $38.49 | +3.92% | 6 | Jul 10, 2025 | |
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.66 | +80.72% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.13 | +76.99% | 4 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $1 → $0.46 | $0.08 | +488.24% | 3 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $4.45 | +124.72% | 3 | May 13, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $5 → $4 | $2.45 | +63.27% | 7 | May 12, 2025 | |
| XNCR Xencor | Maintains: Underweight | $22 → $6 | $7.72 | -22.28% | 2 | May 8, 2025 | |
| KURA Kura Oncology | Maintains: Overweight | $32 → $11 | $6.49 | +69.49% | 1 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $32 → $16 | $7.09 | +125.67% | 8 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $7.35 | +104.08% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $10.06 | +39.17% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.72 | +74.42% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.77 | +69.49% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.43 | +179.72% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $36.07 | +66.34% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $3.42 | +397.08% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $33 | $13.45 | +145.35% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $33.00 | +100.00% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $10.57 | +193.28% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $6.88 | +88.95% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.91 | +451.27% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $1.78 | +97.18% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $101.11 | +260.99% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $36.61 | +25.65% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $450 | $25.72 | +1,649.61% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $3.08 | +1,361.04% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $57.33 | -21.51% | 2 | Jan 23, 2018 |
Replimune Group
Jul 23, 2025
Downgrades: Equal-Weight
Price Target: $17 → $3
Current: $5.09
Upside: -41.06%
Exelixis
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $29 → $40
Current: $38.49
Upside: +3.92%
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.66
Upside: +80.72%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.13
Upside: +76.99%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Underweight
Price Target: $1 → $0.46
Current: $0.08
Upside: +488.24%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $4.45
Upside: +124.72%
Iovance Biotherapeutics
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $2.45
Upside: +63.27%
Xencor
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $7.72
Upside: -22.28%
Kura Oncology
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $6.49
Upside: +69.49%
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $7.09
Upside: +125.67%
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $7.35
Upside: +104.08%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $10.06
Upside: +39.17%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.72
Upside: +74.42%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.77
Upside: +69.49%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.43
Upside: +179.72%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $36.07
Upside: +66.34%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $3.42
Upside: +397.08%
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $13.45
Upside: +145.35%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $33.00
Upside: +100.00%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $10.57
Upside: +193.28%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $6.88
Upside: +88.95%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.91
Upside: +451.27%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $1.78
Upside: +97.18%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $101.11
Upside: +260.99%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $36.61
Upside: +25.65%
Mar 4, 2020
Initiates: Overweight
Price Target: $450
Current: $25.72
Upside: +1,649.61%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $3.08
Upside: +1,361.04%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $57.33
Upside: -21.51%